A Medicare-covered liquid CGP test that identifies an expanded panel of actionable biomarkers.1,2
Expanded panel
with coverage of NTRK fusions,
HRR genes, and bTMB1-3*
Important note: Guardant360 was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
Most validated
with 500+ peer-reviewed
publications
bTMB, blood-based tumor mutation burden; CGP, comprehensive genomic profiling; HRR, homologous recombination repair; NTRK, neurotropic tyrosine receptor kinase.
*HRR genes include BRCA1/2, ATM, PALB2, FANCA, RAD51D, CHEK2, CDK12.¹⁻³
†Average turnaround time from sample receipt to results.
Fast results
in <10 days1†